Press

October 12, 2022 – Today the Society for Clinical Research Sites (SCRS) is pleased to announce the winner of the 2022 Excellence in Patient Centricity award, DM Clinical Research. The award, sponsored by Sanofi, was created to celebrate a clinical research site that places patient experience at the center of its operations. DM Clinical Research won this year’s award by adopting patient-centricity as a measurable and strategic goal for its organization. They started by analyzing their patients’ journeys by communicating directly with trial participants, where they discovered redundancies, confusion and discontinuities in communication. Their team streamlined communication channels and made an effort to tailor to individual patients’ preferred mode (text, email, phone) and time to be contacted, and increased coverage hours to accommodate these preferences. Additionally, they launched a Patient Advocates training program which ensured dedicated personnel at each site solely focused on patient satisfaction. This role included greeting patients, offering regular updates on wait times, and ensuring patient comfort. A patient survey was instituted that allowed their organization to establish a baseline, benchmark between sites and study teams, track progress over time, and continually solicit areas of improvement. SCRS Global Impact Partners (GIPs) and sites cast their nominations for the award, which was eligible to any active SCRS member site. Through an independent judging panel, the winner was selected to receive the award at the SCRS Eagle Award Gala held during the SCRS Global Site Solutions Summit on Saturday, October 8, 2022. “At DM Clinical Research our belief has always been to create systems and processes that are patient-centric and ensure that our core values are not just talked about but operationalized through measurable outcomes,” said Hera Arham, Director of Marketing and Patient Engagement at DM Clinical Research. “We’re incredibly grateful to have won this coveted award and are thankful to our staff, investigators, and most importantly our patients who have contributed to the development of a patient-centric culture through impactful feedback, reliable data, and metrics. We strive to keep patient-centricity at the forefront of all we do.” “Putting patients first is something many industry organizations strive to do but can be challenging to implement. However, we saw many sites this year that went above and beyond to make clinical trials more accessible and convenient for their trial participants,” added Jimmy Bechtel, SCRS VP of Site Engagement. “SCRS applauds DM Clinical Research for their industry-leading initiatives that have improved the patient journey from start to finish. We are honored to help amplify the outstanding work they have done in providing a blueprint for successful patient-centric processes.” For more information about the Excellence in Patient Centricity Award and the SCRS Global Site Solutions Summit, visit sitesolutionssummit.com. About DM Clinical Research DM Clinical is a network of clinical trial sites headquartered in Houston, Texas. Over the past 16 years, DMCR has grown to comprise 12 dedicated research centers and a network of affiliate sites throughout the nation, servicing a range of therapeutic areas, including vaccines, internal medicine, pediatrics, gastroenterology, psychiatry, women’s health, and more. DM Clinical has become a national leader in clinical research and has received industry recognition from the World Vaccine Congress as highly commended for Best Clinical Trial Site. Through its partnerships with prominent global pharmaceutical sponsors, DM Clinical brings opportunities to the community to participate in cutting-edge research, under the careful medical supervision of qualified physicians and professionals. About The Society for Clinical Research Sites Founded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org 410.696.5080

Hanover, MD, September 19, 2022 – The Society for Clinical Research Sites (SCRS) today announced a Global Impact Partnership with Daiichi Sankyo, a global pharmaceutical company based in Japan creating new standards of care through drug research and development. As a Global Impact Partner (GIP), Daiichi Sankyo will engage with SCRS and its members to contribute to the development and implementation of site and patient-focused solutions for the clinical research marketplace. Sean Soth, SCRS Senior Vice President of Strategy & Global Business Partnerships commented, “SCRS is pleased to welcome Daiichi Sankyo to the SCRS Global Impact Partner program. From the start, the Daiichi Sankyo team has provided valuable insights into their approach to site relationships, attending Summits and inviting their global team to understand more about the work SCRS and site members are conducting every day. We look forward to sharing new experiences with Daiichi Sankyo and our community for years to come.”  “At Daiichi Sankyo, our success relies on experts in partnership—our people, scientists, health care providers and advocates. Every practitioner, each passionately bringing their own skill to bear, is essential.  Clinical trial sites are the critical link between our science and the people we seek to help, and being a part of the Society for Clinical Research Sites is an important connection to support smooth, effective and efficient trials that will help us change standards of care,” said Kristine Koontz, PhD, MBA,VP of Global Clinical Operations at Daiihi Sankyo. About Daiichi Sankyo  Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.  About The Society for Clinical Research Sites Founded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/.  Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org 410.696.5080 

Hanover, MD, September 6, 2022 – Today the Society for Clinical Research Sites (SCRS) announced Jackie Kent has joined the organization as its Vice President of Strategy and Special Projects. In this new role, Kent will be representing SCRS at industry conferences and leading key programs such as the SCRS Payment Initiative. Kent brings more than 30 years of experience in IT and clinical development from executive roles with Eli Lilly and Medidata Solutions. She has served on the SCRS Leadership Council for seven years, and is also a board director with Circuit Clinical and current Chair of the Association of Clinical Research Organizations (ACRO). “Jackie has been a tremendous advocate for SCRS since we launched in 2012,” said Allyson Small, SCRS Chief Operating Officer. “SCRS is thrilled to expand its relationship with Jackie in this new role. Her strategic insight and passion will be invaluable to our clinical research site community as we continue to develop site-centric programming.” “Christine Pierre and I often talked about the day that I could be part of the SCRS team, “ shared Kent. “Now it is here. I’m grateful for the opportunity to support this amazing organization that focuses on the sites and patients with everything they do.” About The Society for Clinical Research SitesFounded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org 410.696.5080

Hanover, MD, September 1, 2022 – Today the Society for Clinical Research Sites (SCRS) announced the finalists for the 2022 Site Patient Recruitment Innovation Award (SPRIASM) and Site TankSM Award. SPRIA, sponsored by StudyKIK, recognizes highly successful and unique patient enrollment initiatives executed by sites. Congratulations to this year’s SPRIA finalists: FOMAT Medical Research, IMA Clinical Research, and Javara and SouthCoast Health. Site Tank, sponsored by Pfizer, is a competition for sites to share their innovative technology ideas that enhance, empower and improve research operations. Congratulations to this year’s Site Tank Finalists: University of California – Davis, Research & Me, and DM Clinical Research. “Many sites have been working on creative solutions to address challenges in clinical research,” commented Jimmy Bechtel, SCRS VP of Site Engagement. “The number of submissions we received for this year’s awards echoed that. SCRS is excited to amplify our finalists’ technology ideas and recruitment strategies at the Global Summit. Congratulations to the 2022 finalists!” The SPRIA and Site Tank finalists will present to an audience of sites, Sponsors, CROs and solution providers at the 2022 Global Site Solutions Summit October 7-9 in Hollywood, FL. The winners will be announced at the Eagle Award Gala on October 8. Learn more about SPRIA and Site Tank, and register for the 2022 Global Site Solutions Summit today. About The Society for Clinical Research SitesFounded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org 410.696.5080

Hanover, MD, August 29, 2022 – The Society for Clinical Research Sites (SCRS) today announced a new Site Spark award. The Site Spark award will recognize outstanding and innovative work of research sites that are implementing new and exciting ways to operationalize trials. The award was created to acknowledge forward-thinking sites that have developed unique recruitment methods, championed the use of new technologies, or excelled in diverse, equitable, and inclusive business practices. The inaugural competition will be unveiled at the 2022 European Site Solutions Summit hosted November 14-15 in Lisbon, Portugal. Jimmy Bechtel, SCRS VP of Site Engagement added, “The clinical research landscape is evolving rapidly with new directives, technologies and challenges arising faster than ever. SCRS is excited to celebrate site-driven initiatives that are adaptable, effective, and have that spark that makes our work especially meaningful.” Applications are open to all clinical research sites. Three finalists will be chosen to present their idea at the 2022 European Site Solutions Summit and will receive complimentary registration. The Site Spark award will continue at select SCRS Summits starting in 2023. About The Society for Clinical Research SitesFounded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org 410.696.5080

Hanover, MD, July 25, 2022 – The Society for Clinical Research Sites (SCRS) today announced the Sponsor and CRO finalists for the 2022 SCRS Eagle Award. The Eagle Award recognizes CROs and Sponsors that have shown outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships. The finalists were selected from nominations provided by clinical research sites around the world. Voting is now open to all clinical research site professionals and closes on August 26, 2022. The 2022 Sponsor nominees are: Eli Lilly, Janssen, the Pharmaceutical Companies of Johnson & Johnson, Merck, Moderna, Novartis, Pfizer and Roche The 2022 CRO nominees are: ICON plc, IQVIA, Labcorp, Parexel, PPD, and Syneos Health Sean Soth, SCRS Senior Vice President of Strategy & Global Business Partnerships commented, “As SCRS celebrates 10 years of advancing site success, what the Eagle Award represents has been an integral component to that mission. Effective partnerships and collaboration between sites and the organizations they work with impacts site sustainability as well as our patients. SCRS congratulates the 2022 finalists and looks forward to honoring the recipients at the 2022 Global Site Solutions Summit.” About The Society for Clinical Research SitesFounded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org 410.696.5080

Hanover, MD, July 7, 2022 – The Society for Clinical Research Sites (SCRS) has issued a response to the new required form issued on July 1, 2022 by the Centers for Medicare & Medicaid Services (CMS) which impacts how routine care covered by Medicaid in qualifying clinical trials should be billed by clinical research sites and healthcare providers. This form is a new requirement under a recently passed federal law (Section 210 of the Consolidated Appropriations Act of 2021) that requires all states’ Medicaid programs to cover such services. SCRS and industry stakeholders have expressed that the addition of this required form may decrease clinical trial enrollment of Medicaid beneficiaries and will subsequently impact opportunities for increased diversity, equity and inclusion of trials. Additionally, the form will increase research site costs due to the extra work needed to complete the form as well as compliance risk and tracking. SCRS has already successfully worked with CMS to develop a more streamlined form compared to the original draft issued 6 months ago. The discussions resulted in having the scope clarified as well as simplifying the process to complete the form. More information about SCRS’ accepted revisions, as well as helpful information for industry partners regarding the form, can be found on the SCRS website. “SCRS was pleased that CMS listened to the voice of the sites and made major revisions to the final form,” commented David Vulcano, SCRS Honorary President. “However, concerns still remain that the legal requirement of this form will increase clinical research site costs and decrease enrollment of Medicaid beneficiaries in clinical trials. We are keenly interested in hearing the site experience with this issue and evidence of its impact, both positive and negative.” As Medicaid is a state-run program, it is critical for clinical trial sites and affiliated providers that expect to bill Medicaid for routine care in qualifying trials to receive guidance from state Medicaid programs on when and how they expect the form to be utilized and archived. SCRS is continuing to educate Congress on this issue and has requested sites share their experience with its implementation. To share comments, please contact communications@myscrs.org. About The Society for Clinical Research SitesFounded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org 410.696.5080

Hanover, MD, July 6, 2022 – The Society for Clinical Research Sites (SCRS) today announced that Transformative Pharmaceutical Solutions (TPS), a customized outsourcing solution for clinical and site operations, has joined the organization’s Global Impact Partner (GIP) program. The program is comprised of industry sponsors, CROs and solution providers committed to supporting SCRS and its site members through continued industry collaboration, education, dialogue, and mentorship. Becoming a GIP demonstrates TPS’ commitment to understanding site needs to continue sustainable trials. “TPS is thrilled to be a Global Impact Partner and we are excited to contribute to the goals of making a better research ecosystem,” said Jeff Repper, EVP of Site Operations at TPS. “Our mission is to provide Sponsors with the ability to invest in the infrastructure of their clinical research sites, improving study conduct and quality while enhancing the patient experience. Our solution, SiteChoice™, enables this by providing therapeutically aligned and experienced resources to better manage the patients’ journey.” “The clinical research workforce is experiencing ongoing staffing challenges that include: project management skills gaps, patient-facing staff attrition, and a shrinking professional pool. TPS is helping bridge the workforce gap by providing experienced clinical teams, operational efficiencies and new technology to conduct trials. TPS has prioritized enhancing industry-site relationships through its trial management offerings and will provide a unique perspective to the SCRS Global Impact Partner program,” commented Sean Soth, SVP of Strategy & Global Business Partnerships for SCRS. About Transformative Pharmaceutical Solutions TPS is a clinical research solutions company focused on deploying strategic resources empowered by technology; designed to address critical development needs across the industry. Our SiteChoice™ solution provides Sponsors with the ability to invest in the infrastructure of their clinical research sites, improving study conduct and quality while enhancing patient recruitment and experience. About The Society for Clinical Research Sites Founded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org

Hanover, MD, June 25, 2022 – Today the Society for Clinical Research Sites (SCRS) announced Nicole Mills has joined as the organization’s new Education & Knowledge Management Lead. Mills has more than ten years of experience in the clinical research industry including working extensively with clinical research sites. Mills will oversee educational content for SCRS events and programs and work to provide clinical research sites with industry-leading professional development opportunities through webinars, symposiums, summits, and more. “SCRS is committed to developing cutting-edge content and resources to address industry-wide challenges,” said Jimmy Bechtel, SCRS Vice President of Site Engagement. “Nicole has been a valuable contributor to SCRS in the past and her site-focused experience will provide valuable insights to our educational programming for sites and industry.” “SCRS has been integral in my career development and continuing education in clinical research. I am thrilled to partner with them in delivering that same level of education to our industry partners and members as a part of the SCRS team,” shared Mills. About The Society for Clinical Research SitesFounded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org

Hanover, MD, June 21, 2022 – The Society for Clinical Research Sites (SCRS) is pleased to announce that H1 is now a patron sponsor of the SCRS Diversity Awareness Program. SCRS developed its Diversity Awareness Program to engage industry stakeholders in this important dialogue and develop resources to strengthen site preparedness for effective recruitment of diverse patients. Through this partnership, H1 will align with other Sponsors, CROs and industry solution providers committed to improving diverse representation and engagement in clinical trials. “Inclusion is the precursor to building trust between patients and doctors and the bridge leading to a more equitable healthcare system for all. Every day we work with top 20 pharma companies to build equitable clinical trial strategies,” said Ariel Katz, Co-Founder and CEO of H1. “In order to achieve true equity in healthcare, diversity needs to be fostered and improved at every step of the drug product life cycle, from research to clinical studies and post-approval communication and education. Along this entire path, the organization must ensure that diverse voices are included and the needs of diverse patient populations are taken into account. That is why we wanted to support and sponsor the valuable contributions of SCRS to increase diversity within clinical trials.” “H1 is not only committed to increasing diverse participants in clinical trials, but also ensuring investigators working at clinical research sites are representative of those communities and can engage in meaningful ways,” said VP of Strategy and Special Projects, Diana Foster. “H1’s commitment to the SCRS Diversity Awareness Program will support SCRS in sharing and developing resources, knowledge and best practices that will help industry meet FDA’s diverse enrollment initiatives.” About H1H1 is the connecting force for global HCP, clinical, scientific and research information. The H1 Connect platform democratizes access to HCP knowledge and groundbreaking insights for life sciences, academic medical institutions, health systems, and payors. H1 Connect fuels a robust product that helps customers discover and engage industry experts, drive equitable research, access groundbreaking science, and accelerate commercial success with the most robust and accurate healthcare professional data. Trial Landscape is H1’s clinical trial platform that combines diversity and inclusion data for principal investigators and patient segments in addition to providing a complete understanding of the clinical trial landscape.  Learn more at h1.co. About The Society for Clinical Research Sites Founded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Anya Nelson Scratch Marketing + Media for H1 anyan@scratchmm.com M: 617.817.6559

Hanover, MD, June 13, 2022 – The Society of Clinical Research Sites (SCRS) is pleased to announce Peter Fredette, Oncology Strategic Site Solutions Director at IQVIA, as the new Global Oncology Site Solutions Summit Committee Chair. Comprised of experts from research sites, CROs, and Sponsors in oncology clinical research and patient care, the SCRS Oncology Board creates greater efficiency and sustainability for sites working with oncology patients through education, research, and resources. Peter Fredette commented, “As an advocate for and contributor to SCRS Oncology from the very beginning, I am always thinking about ways the program can grow and evolve. Every SCRS Summit I attend results in great personal and professional value. This community of research sites and site advocates is unlike any other, and I’m proud to be a member. I am honored to be nominated and humbly accept the SCRS Oncology Board Chair position. Like my esteemed predecessors, I commit to continuing the program’s focus on oncology research site advocacy and sustainability. I urge all oncology research sites to join the community, the conversation, and the collaborative. What we do TOGETHER in the next couple of years can be truly transformational, if we take full advantage of the current industry tailwinds.” “Peter has made valuable contributions to the SCRS Oncology program and Oncology Site Solutions Summit for many years, including leading efforts to develop a Phase 1 Guidance Document for Sites and advising our Oncology Summit content development,” said Jimmy Bechtel, VP of Site Engagement and SCRS Oncology Program co-lead. “With the addition of Peter’s input and guidance, the program will continue to encourage collaboration and process efficiency within the oncology community.” About The Society for Clinical Research SitesFounded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/.

Hanover, MD, June 6, 2022 – The Society for Clinical Research Sites (SCRS) announced today that Clinerion has joined the organization as a Global Impact Partner (GIP). SCRS’ GIP Program provides a unique opportunity for sponsors, CROs and solution providers to engage and collaborate with SCRS and its site members. Becoming a GIP demonstrates Clinerion’s commitment to developing a deeper understanding of the needs of sites and contribute to the development of solutions in the clinical research marketplace. Sean Soth, SCRS Senior Vice President of Strategy & Global Business Partnerships shared, “Intelligent patient data and analytics will be a pathway for site sustainability in the years ahead.  Clinerion’s support of sites and their experience with patient search efficiency will provide unique insights for our audiences and industry. SCRS welcomes the Clinerion team’s ideas, dedication and insight to the Global Impact Partner program.” “Clinerion is looking forward to a great collaboration with the SCRS as a GIP member, based on our mutual principles of supporting clinical trial sites with access to trials, improving trial efficiency and sharing best practices,” said Luis Magalhaes, Clinerion’s Customer Solutions Director. “Clinerion’s worldwide network of hospitals can benefit greatly from the SCRS’ expertise and we expect SCRS will benefit from Clinerion’s global reach as they expand beyond the USA. We have great expectations of our contacts with SCRS sites and the other GIP members.” About Clinerion Clinerion accelerates clinical research and medical access to treatments for patients. We generate real-world data from our global network of partner hospitals for Real World Evidence analyses. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. Researchers gain access to real-time, longitudinal patient data from electronic health records for analysis. We enable pharmaceutical companies, CROs and SMOs to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s Patient Network Explorer also provides a platform for integration of diverse patient data sources into real-world data ecosystems. Clinerion’s proprietary technologies comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland. About The Society for Clinical Research SitesFounded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Le Vin Chin Director, Head of Marketing & Communications Clinerion Ltd Elisabethenanlage 11, 4051 Basel, Switzerland Tel.: +41 61 865 60 54 mailto:media@clinerion.com Marissa HillCommunications ManagerSociety for Clinical Research Sitescommunications@myscrs.org

Hanover, MD, May 31, 2022 – Today the Society for Clinical Research Sites (SCRS) announced Clinical ink has joined the organization as a Global Impact Partner (GIP). As a GIP, Clinical ink will participate on the SCRS Global Impact Board at an executive level and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS. Sean Soth, SCRS Senior Vice President of Strategy & Global Business Partnerships shared, “SCRS is proud to welcome Clinical ink to our community. This partnership with SCRS illustrates Clinical ink’s pledge to acknowledge site feedback and develop strong, sustainable sites. SCRS Global Impact partners are accelerating collaboration amongst industry stakeholders and Clinical ink’s valuable expertise will add even more momentum to our mission.” “We see sites as the lifeblood of clinical research and development—they currently make and will continue to make clinical research work,” said Lane Nichols, Executive Vice President of Product at Clinical ink. “This partnership gives Clinical ink another opportunity to work alongside research sites to learn and optimize our solutions and processes. Together, we can best serve patient needs and power patient science in clinical research.” About Clinical ink Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience. About The Society for Clinical Research SitesFounded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org +1 267.865.3296

Hanover, MD, May 4, 2022 – The Society for Clinical Research Sites (SCRS) today announced the release of a toolkit created by several of its largest site network members to address the clinical research industry’s workforce challenges and inflationary pressures. The Site Toolkit for Challenges in Workforce Retention and Inflation is available to SCRS member sites and offers best practices to maximize revenue, minimize costs, and recruit and retain employees. A companion deliverable to the toolkit is an open letter to industry Sponsors and CROs, outlining current challenges sites face with staffing and budgeting, and solutions urgently needed to address those issues. “The goal of these tools is to encourage an honest dialogue about the industry’s shared responsibility to each other during this especially challenging time,” said Allyson Small, Chief Operating Officer of SCRS. “It’s imperative that we address these issues now to ensure we have a viable research infrastructure required to continue to conduct safe and effective clinical trials at scale, whether traditional or hybrid.” William Smith, CEO of Alliance for Multispecialty Research and SCRS Task Force Committee co-chair added, “Sites are increasingly challenged by both inflation and the even more accelerated costs of healthcare workers. The data and best practices SCRS has collected through this Task Force Committee will be instrumental to help sites and industry work together to reach mutually-beneficial solutions.” “While SCRS members are working with each other in sharing best practices to address these headwinds, even our most experienced site leaders state they cannot pull through this alone,” commented David Vulcano, Honorary President of SCRS. “They need help from sponsors, CROs, and other stakeholders involved in clinical trials and the progress of new therapies.” SCRS encourages all sites and industry partners to share the letter with their respective organizations and networks. SCRS will continue to host meaningful discussions between industry sponsors, CROs, solution providers, and sites through webinars, Site Solutions Summit sessions, and Sites NOW meetings. Suggestions for other solutions or resources to address site workforce and inflation challenges can be submitted to the SCRS leadership team at info@myscrs.org. About The Society for Clinical Research SitesFounded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org 267.865.3296

Company’s PPD clinical research business to share expertise in recruiting diverse patient populations Hanover, MD, May 3, 2022 – The Society for Clinical Research Sites (SCRS) today announced that Thermo Fisher Scientific Inc., the world leader in serving science, has made a commitment through its PPD clinical research business to become an Oncology Spirit Partner and a funding sponsor of the SCRS Diversity Awareness Program. Oncology Spirit Partners serve on the SCRS Oncology Advisory Board and take leadership roles in the SCRS Oncology Program and Strategic Working Groups. Spirit Partners are actively involved in the annual SCRS Global Oncology Site Solutions Summit, including exhibiting, speaking and hosting a Site Partnership Symposium. “SCRS Oncology Spirit Partners are vital to helping SCRS address issues that oncology sites are facing today,” commented Marcus Malek, SCRS Director of Global Business Partnerships. “SCRS is eager to showcase the PPD clinical research business’ valuable expertise as an Oncology Spirit Partner as we work together to increase the efficiency and effectiveness of oncology clinical research sites globally.” Through the Diversity Awareness Program, SCRS has not only helped sites explore and understand the factors that drive successful recruitment of diverse patient populations but also created an assessment tool to guide sites in improving their ability to recruit diverse patient populations. The PPD clinical research business will be integrated with the SCRS Diversity Program’s working group of supporters to establish best site practices for diverse patient engagement in clinical research, as well as engaging directly with sites via SCRS webinars, summits and publications. Diana Foster, VP of Strategy and Special Projects for SCRS commented, “The PPD clinical research business has been a valued contributor to SCRS for several years and has consistently demonstrated their commitment to site sustainability. Their engagement in this program will directly support ongoing research that will aid sites in recruiting and engaging diverse patients. SCRS looks forward to collaborating with them to address this industry-wide need.” “It’s vital that clinical trials include participation by patients representing the diversity of the overall population to ensure the efficacy and effectiveness of promising new treatments for all people,” said David M. Johnston, Ph.D., Senior Vice President and President, Clinical Research, Thermo Fisher Scientific. “Through our collaboration with SCRS, we are able to exchange best practices and hear the ‘voice of the site’ to continually improve trial conduct strategy and execution on behalf of customers and for patients in need.” Last year, the PPD clinical research business was named the winner of SCRS’ prestigious Eagle Award for its commitment to advancing clinical research professionalism through strong site partnerships. The award, based on voting by research sites globally, recognizes the clinical research organization that best exemplifies a site-focused approach to clinical trial management by demonstrating outstanding leadership, professionalism and integrity. ### About The Society for Clinical Research SitesFounded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit myscrs-new.local/. Contact: Marissa Hill Communications Manager Society for Clinical Research Sites communications@myscrs.org 410.696.5080 x150